With $45 million in series A money, Neurogastrx Inc. has enough to pay for proof-of-concept work with NG-101, a peripherally restricted dopamine D2/D3 receptor antagonist for gastroparesis, an indication that involves delayed emptying of the stomach – and one that's proved tricky for drug developers.